由FDA批准的新药物 Sotagliflozin在糖尿病患者中将心脏病发作和中风风险降低23%。 New FDA-approved drug sotagliflozin cuts heart attack and stroke risks by 23% in diabetes patients.

一种由林业发展局批准的治疗2型糖尿病和肾病的新药物Sotagliflozin,在减少心血管风险因素患者的心脏病发作和中风风险方面大有希望。 A new FDA-approved drug, sotagliflozin, for treating type 2 diabetes and kidney disease shows significant promise in reducing heart attack and stroke risks among patients with cardiovascular risk factors. 根据对《柳叶刀糖尿病和内分泌学》的一项研究,这一发现标志着SGLT抑制剂首次表现出这种独特的好处。 This finding, from a study in The Lancet Diabetes & Endocrinology, marks the first time an SGLT inhibitor has shown such unique benefits. 与安慰剂相比,导致心脏病发作、中风和死亡率下降23%。 The drug works by blocking proteins that control blood sugar, leading to a 23% reduction in heart attack, stroke, and death rates compared to a placebo.